In summary, this study is significant as it provides evidence that for symptomatic adenomyosis, focal or diffuse, MRgFUS can be used as a safe and effective treatment modality for immediate as well as sustained improvement in quality of life, especially in respect to the most significant symptoms of heavy menstrual bleeding and dysmenorrhoea, without any add back treatment such as GNRH analogues or Levonorgestrel IUD (LNG). The gene discussed is GNRH1; the disease is Dysmenorrhea.